{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:20:11Z","timestamp":1778617211663,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017A5TXC3"],"award-info":[{"award-number":["2017A5TXC3"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["20017"],"award-info":[{"award-number":["20017"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.coph.2021.07.010","type":"journal-article","created":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T22:44:20Z","timestamp":1630277060000},"page":"216-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Nonsteroidal mineralcorticoid receptor antagonists: Novel therapeutic implication in the management of patients with type 2 diabetes"],"prefix":"10.1016","volume":"60","author":[{"given":"E.A.","family":"Greco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Feraco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Marzolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mirabelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Armani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Caprio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.07.010_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.metabol.2018.10.007","article-title":"Genetics and epigenetics in obesity","volume":"92","author":"Rohde","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.coph.2021.07.010_bib2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.physbeh.2007.10.010","article-title":"The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance","volume":"94","author":"Goossens","year":"2008","journal-title":"Physiol Behav"},{"key":"10.1016\/j.coph.2021.07.010_bib3","doi-asserted-by":"crossref","first-page":"182753","DOI":"10.1155\/2013\/182753","article-title":"Trunk fat negatively influences skeletal and testicular function in obese men: clinical implication for the aging male","volume":"2013","author":"Migliaccio","year":"2013","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.coph.2021.07.010_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12944-015-0123-1","article-title":"The role of fatty acids in insulin resistance","volume":"14","author":"Sears","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.coph.2021.07.010_bib5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2021.07.010_bib6","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1210\/jc.2008-0251","article-title":"Primary Aldosteronism Prevalence in Hypertension Study Investigators: body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients","volume":"93","author":"Rossi","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.010_sref7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1210\/en.2010-0674","article-title":"Anti adipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome","volume":"152","author":"Caprio","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2021.07.010_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvp191","article-title":"Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice","volume":"84","author":"Hirata","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.coph.2021.07.010_sref9","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1096\/fj.13-245415","article-title":"Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice","volume":"28","author":"Armani","year":"2014","journal-title":"FASEB Journal"},{"key":"10.1016\/j.coph.2021.07.010_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2019.11.006","article-title":"Mineralocorticoid receptors in metabolic syndrome: from physiology to disease","volume":"31","author":"Feraco","year":"2020","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.coph.2021.07.010_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/JOE-17-0351","article-title":"Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance","volume":"235","author":"Wada","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.coph.2021.07.010_bib12","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa0808718","article-title":"Cold-activated brown adipose tissue in healthy men","volume":"360","author":"van Marken Lichtenbelt","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.010_sref13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/dom.13539","article-title":"Mineralocorticoid antagonism enhances brown adipose tissue function in humans: a randomized placebo-controlled cross-over study","volume":"21","author":"Thuzar","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.coph.2021.07.010_bib14","first-page":"e42","article-title":"Finerenone and chronic kidney disease outcomes in type 2 diabetes. Reply","volume":"384","author":"Bakris","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.010_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nature05483","article-title":"Adipocytes as regulators of energy balance and glucose homeostasis","volume":"444","author":"Rosen","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.07.010_bib16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1242\/dmm.009662","article-title":"The adipose organ at a glance","volume":"5","author":"Cinti","year":"2012","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.coph.2021.07.010_bib17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1172\/JCI3155","article-title":"Emergence of brown adipocytes in white fat in mice is under genetic control. Effects on body weight and adiposity","volume":"102","author":"Guerra","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.coph.2021.07.010_bib18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/366740a0","article-title":"Development of obesity in transgenic mice after genetic ablation of brown adipose tissue","volume":"366","author":"Lowell","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.07.010_bib19","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa0810780","article-title":"Identification and importance of brown adipose tissue in adult humans","volume":"360","author":"Cypess","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.010_sref20","first-page":"1","article-title":"The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway","author":"Marzolla","year":"2020","journal-title":"FASEB Journal"},{"key":"10.1016\/j.coph.2021.07.010_bib21","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM196511182732106","article-title":"Hypertension, the potassium ion and impaired carbohydrate tolerance","volume":"273","author":"Conn","year":"1965","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.010_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/HYPERTENSIONAHA.114.04981","article-title":"Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase","volume":"66","author":"Urbanet","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2021.07.010_bib23","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1096\/fj.06-7970com","article-title":"Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis","volume":"21","author":"Caprio","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2021.07.010_bib24","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1210\/endo.132.6.8504747","article-title":"Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes","volume":"132","author":"Rondinone","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2021.07.010_bib25","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/ijo.2014.68","article-title":"Mineralocorticoid vs glucocorticoid receptors: solo players or team mates in the control of adipogenesis?","volume":"38","author":"Armani","year":"2014","journal-title":"Int J Obes"},{"key":"10.1016\/j.coph.2021.07.010_bib26","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1210\/en.2013-1115","article-title":"Antioxidant N-acetylcysteine protects pancreatic beta-cells against aldosterone-indiced oxidative stress and apoptosis in female db\/db mice and insulin-producing MIN6 cells","volume":"154","author":"Jin","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2021.07.010_bib27","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","article-title":"Aldosterone decreases glucose-stimulated insulin secretion in\u00a0vivo mice and in murine islets","volume":"54","author":"Luther","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2021.07.010_bib28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.107.708537","article-title":"Multi marker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study","volume":"116","author":"Ingelsson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2021.07.010_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.HYP.25.1.30","article-title":"Relationship among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans","volume":"25","author":"Goodfriend","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2021.07.010_bib30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1055\/s-0031-1284367","article-title":"ERK1\/2 MAPKs and Wnt signaling pathways are independently involved in adipocytokine-mediated aldosterone secretion","volume":"119","author":"Vleugels","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.coph.2021.07.010_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabet.2019.02.003","article-title":"Links between aldosterone excess and metabolic complications: a comprehensive review","volume":"46","author":"Bothou","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.coph.2021.07.010_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1054\/plef.2002.0414","article-title":"An oxidized derivate of linoleic acis affects aldosterone secretion by adrenal cells in\u00a0vitro","volume":"67","author":"Goodfriend","year":"2002","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.coph.2021.07.010_bib33","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2021.07.010_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.mce.2011.09.011","article-title":"The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism","volume":"350","author":"Marzolla","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.coph.2021.07.010_bib35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2021.07.010_bib36","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2337\/db06-1749","article-title":"Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels","volume":"56","author":"Nishimura","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2021.07.010_bib37","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1210\/jc.2006-1055","article-title":"Relationship between adipocyte size and adipokine expression and secretion","volume":"92","author":"Skurk","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2021.07.010_bib38","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.molmet.2017.07.008","article-title":"Activated macrophages control human adipocyte mitochondrial bioenergetics via secreted factors","volume":"6","author":"Keuper","year":"2017","journal-title":"Mol Metabol"},{"key":"10.1016\/j.coph.2021.07.010_bib39","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2021.07.010_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jsbmb.2013.02.012","article-title":"Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity","volume":"137","author":"Feraco","year":"2013","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.coph.2021.07.010_bib41","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/sj.ijo.0803642","article-title":"Human adipocytes induce an ERK1\/2 MAP kinase-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells","volume":"31","author":"Krug","year":"2007","journal-title":"Int J Obes"},{"key":"10.1016\/j.coph.2021.07.010_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ando.2018.04.018","article-title":"UCP1 transrepression in brown fat in\u00a0vivo and mineralocorticoid receptor anti-thermogenic effects","volume":"80","author":"Kuhn","year":"2019","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.coph.2021.07.010_bib43","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.4161\/auto.5.8.9991","article-title":"Targeted deletion of autophagy-related 5 (atg5) impairs adipogenesis in a cellular model and in mice","volume":"5","author":"Baerga","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.coph.2021.07.010_sref44","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years OF mineralcorticoid receptor: mineral corticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.coph.2021.07.010_bib45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2021.07.010_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.coph.2021.07.010_bib47","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A\u00a0randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2021.07.010_sref48","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.13219","article-title":"Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice","author":"Pieronne-Deperrois","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.coph.2021.07.010_bib49","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/dom.13393","article-title":"Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction","volume":"20","author":"Lachaux","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.coph.2021.07.010_sref50","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"2012 Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2021.07.010_bib51","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) study group: effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2021.07.010_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jash.2016.06.021","article-title":"2016 Masked and nocturnal hypertension in the ARTS-DN ABPM sub-study with finerenone","volume":"10","author":"Ruilope","year":"2016","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.coph.2021.07.010_sref53","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"FIGARO-DKD study investigators: design and baseline characteristics in the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.coph.2021.07.010_bib54","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"On behalf of the FIDELIO-DKD study investigators: FIDELIO-DKD study investigators: design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.coph.2021.07.010_sref55","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"FIDELIO-DKD Investigators: finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148922100103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147148922100103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:50:17Z","timestamp":1778615417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147148922100103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":55,"alternative-id":["S147148922100103X"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.07.010","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonsteroidal mineralcorticoid receptor antagonists: Novel therapeutic implication in the management of patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}